BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1148 related articles for article (PubMed ID: 26112067)

  • 1. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
    Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
    Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress on pyrazole scaffold-based antimycobacterial agents.
    Keri RS; Chand K; Ramakrishnappa T; Nagaraja BM
    Arch Pharm (Weinheim); 2015 May; 348(5):299-314. PubMed ID: 25820461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments of coumarin-containing derivatives and their anti-tubercular activity.
    Hu YQ; Xu Z; Zhang S; Wu X; Ding JW; Lv ZS; Feng LS
    Eur J Med Chem; 2017 Aug; 136():122-130. PubMed ID: 28494250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review on Coumarin Derivatives as Potent Anti-tuberculosis Agents.
    Mujeeb S; Singh K; Yogi B; Ansari V; Sinha S
    Mini Rev Med Chem; 2022; 22(7):1064-1080. PubMed ID: 34579635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinoline: a promising antitubercular target.
    Keri RS; Patil SA
    Biomed Pharmacother; 2014 Oct; 68(8):1161-75. PubMed ID: 25458785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coumarin hybrid derivatives as promising leads to treat tuberculosis: Recent developments and critical aspects of structural design to exhibit anti-tubercular activity.
    Reddy DS; Kongot M; Kumar A
    Tuberculosis (Edinb); 2021 Mar; 127():102050. PubMed ID: 33540334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
    Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
    Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of coumarin derivatives as inhibitors of Mycobacterium bovis (BCG).
    Rezayan AH; Azerang P; Sardari S; Sarvary A
    Chem Biol Drug Des; 2012 Dec; 80(6):929-36. PubMed ID: 22943459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and bioactivity of antitubercular peptides and peptidomimetics: an update.
    De Leon Rodriguez LM; Kaur H; Brimble MA
    Org Biomol Chem; 2016 Jan; 14(4):1177-87. PubMed ID: 26645944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationships of phenyl-substituted coumarins with anti-tubercular activity that target FadD32.
    Kawate T; Iwase N; Shimizu M; Stanley SA; Wellington S; Kazyanskaya E; Hung DT
    Bioorg Med Chem Lett; 2013 Nov; 23(22):6052-9. PubMed ID: 24103299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triazole: A Promising Antitubercular Agent.
    Keri RS; Patil SA; Budagumpi S; Nagaraja BM
    Chem Biol Drug Des; 2015 Oct; 86(4):410-23. PubMed ID: 25643871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in new structural classes of anti-tuberculosis agents.
    Nayyar A; Jain R
    Curr Med Chem; 2005; 12(16):1873-86. PubMed ID: 16101507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationship of natural and synthetic coumarin derivatives against
    Pires CT; Scodro RB; Cortez DA; Brenzan MA; Siqueira VL; Caleffi-Ferracioli KR; Vieira LC; Monteiro JL; CorrĂȘa AG; Cardoso RF
    Future Med Chem; 2020 Sep; 12(17):1533-1546. PubMed ID: 32820960
    [No Abstract]   [Full Text] [Related]  

  • 17. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
    Poce G; Cocozza M; Consalvi S; Biava M
    Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, biological evaluation, and structure-activity relationships for 5-[(E)-2-arylethenyl]-3-isoxazolecarboxylic acid alkyl ester derivatives as valuable antitubercular chemotypes.
    Pieroni M; Lilienkampf A; Wan B; Wang Y; Franzblau SG; Kozikowski AP
    J Med Chem; 2009 Oct; 52(20):6287-96. PubMed ID: 19757815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances of pyrazole-containing derivatives as anti-tubercular agents.
    Xu Z; Gao C; Ren QC; Song XF; Feng LS; Lv ZS
    Eur J Med Chem; 2017 Oct; 139():429-440. PubMed ID: 28818767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
    Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
    Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.